FAS and synovial sarcoma: sCD95L could thus act as an inhibitor of CD95-mediated AICD in these contexts, promoting effector T-cell proliferation and tissue lesions, as demonstrated for antoantigen-reactive CD4 T cells in SS mouse models [212].